Can The Class Action Lawsuit Against Lance Armstrong Actually Work?

The Lance Armstrong saga continues (we've written on Lance HERE, HERE, HERE)... this week saw a class action lawsuit filed against Lance Armstrong and various publishers on behalf of California consumers who claim they were misled by Defendants' statements and purchased Defendant Armstrong's books based upon the false belief that they were true and honest works of nonfiction.

When I first heard about the class action, I immediately thought "Are you kidding me?  Sure, we'd all like to sue Oliver Stone for subjecting us to JFK in 10th grade history class but this? ... come on."

SO, is this class action against Lance Armstrong legit? Actually, it might be.

Stutzman, et al v Lance Armstrong, et al, filed January 22, 2013 in the US District Court for the Eastern District of California, alleges Lance Armstrong et al, made multiple misrepresentations contained in Lance Armstrong's books, IT'S NOT ABOUT THE BIKE: My JOURNEY BACK TO LIFE and EVERY SECOND COUNTS, and advertisements and marketing for the books (including the front and back cover and flyleafs media press kits, during television and newspaper interviews, on Internet websites and at personal appearances made by Armstrong) as true and honest works of nonfiction when, in fact, Defendants knew or should have known that these books were works of fiction. Further, the lawsuit claims Lance Armstrong et al advertised marketed and sold these books as a works of nonfiction.

The Plaintiffs allege they were misled by Lance Armstrong's and the other Defendants' statements and purchased Lance Armstrong's books based upon the false belief that they were true and honest works of nonfiction. In their 59-page Complaint, Plaintiffs cite to the exhaustive and growing body of evidence and recent admissions by Lance Armstrong himself to support the allegations of misrepresentation and fraud regarding Lance Armstrong’s use of banned substances (EPO, blood doping, testosterone) during his professional cycling career.

Knowing that the mere claim that his success was due to superior physical training, proper diet and an extraordinary spirit and drive to succeed was not enough to quell suspicions and rumors that he doped, Defendant Armstrong wrote lengthy passages in IT'S NOT ABOUT THE BIKE: My JOURNEY BACK TO LIFE that were intended to convince readers and consumers - including Plaintiffs and the members of the Class - that the rumors of Armstrong's doping were unfair and untrue because of the extensive drug-testing regime employed by the DCI and the organizers of the Tour de France... Complaint ¶ 20

In order to survive a motion to dismiss, the Plaintiffs will have to overcome the pleading requirements of Federal Rule of Civil Procedure 9(b) which requires state-law claims grounded in fraud to be plead with particularity and requires a plaintiff to plead with particularity the circumstances constituting the fraud while malice, intent, knowledge, and other conditions of a person's mind may be alleged generally. “Averments of fraud must be accompanied by the ‘who, what, when, where, and how’ of the misconduct charged.” Yess v. Ciba–Geigy Corp. USA; Villegas v. Wells Fargo Bank, N.A. (N.D. Cal. Sept. 17, 2012).

The Complaint almost certainly meets Rule 9(b)’s requirements as to Lance Armstrong. As to the other named Defendants however, the Plaintiffs may not get so far. This lawsuit was brought in a Federal Court in the Eastern District of California – a court within the jurisdiction of the 9th Circuit. The United States Court of Appeals for the 9th Circuit has held that a book publisher owed no duty to a car dealership owner for allegedly publishing errors concerning emission systems in automobiles. Sinai v. Mitchell Books (9th Cir.1993). In 2000, a New York court followed the 9th Circuit’s lead and supported the proposition that publishers have no duty to investigate the accuracy of its books.

The Sinai court stated that absent an express warranty, publishers have no duty to investigate the accuracy of the contents of the books it publishes and concluded that such a duty could not be created because a publisher's right to publish free of fear of liability is guaranteed by the First Amendment and the overriding societal interest in the untrammeled dissemination of knowledge. While the Sinai case is 20 years old and may be revisited or distinguished at this point, it may be that the “deep pockets” of the publishers in the case might not be reachable by the Plaintiffs. Which would leave Lance Armstrong alone to pay any judgment.

This case will be interesting to watch in light of Lance Armstrong's recent admissions, alleged recent lies, and anticipated flood of lawsuits resulting therefrom.  If the case is permitted to move forward it will no doubt be because of Lance Armstrong's years of agressive lies and denials about his drug use during his cycling career.  The crux of the case is the contention that the Plaintiffs would not have purchased the books had the truth not been withheld by Lance Armstrong. 

The Boulder Business Lawyers at Laszlo & Associates, LLC provide legal counsel for businesses on a variety of business needs, including products liability, risk management, corporate protection, and legal compliance.

Supreme Court Wal-Mart Class Action Decision - Commonality is King

The Supreme Court's recent decision in the Wal-Mart sex-descrimination suit demonstrates the importance of 'commonality' in class actions.  Not to mention that the decision is a good example of why MDLs, free from such 'roadblocks', are the new class actions.  Because MDLs are not regulated in the way class actions are, such a review for lack of commonality reasonably would never occur.

The plaintiffs' case against Wal-Mart was based on an alleged pattern of descrimination in the form of paying women workers less than thier male counterparts and providing them fewer opportunities.  In the end, the allegations were not enough to permit the three named plaintiffs to represent a class of 1.6 million.

Merely showing that Wal-Mart's policy of descrimination has produced an overall sex-based disparity does not suffice. - Justice Scalia. 

 

The "Sunshine In Litigation Act of 2011" May Shed Too Much Light Into The Discovery Process

There has been a lot of rumbling over Senate Bill 623 aka the “Sunshine in Litigation Act of 2011” lately.  Perhaps for good reason.  S. 623 provides in part that:

In any civil action in which the pleadings state facts that are relevant to the protection of public health or safety, a court shall not enter, by stipulation or otherwise, an order otherwise authorized under rule 26(c) of the Federal Rules of Civil Procedure restricting the disclosure of information obtained through discovery, an order approving a settlement agreement that would restrict the disclosure of such information, or an order restricting access to court records unless in connection with such order the court has first made independent findings of fact that--

‘(A) such order would not restrict the disclosure of information which is relevant to the protection of public health or safety; or

‘(B)(i) the public interest in the disclosure of past, present, or potential health or safety hazards is outweighed by a specific and substantial interest in maintaining the confidentiality of the information or records in question; and

‘(ii) the requested order is no broader than necessary to protect the confidentiality interest asserted.

It is certainly understandable why attorneys on either side of the v. would react strongly to S. 623.  Defendants certainly want to protect and direct litigation through discovery strategy.  Such tactics are necessary and effective.  Plaintiffs clearly would benefit from a defendant's fear that a scorched earth discovery effort could uncover damaging documents and that, those facts, if made public, would be highly detrimental to the business. 

S. 623 may be vunerable to loose interpretation resulting in unintended consequnses that inflict considerable damage to parties unable to protect information.  Yet, a middle ground has to be found on this issue.  Bringing a lawsuit cannot be made to give a plaintiff carte blanche to discover and make public anything it wants.  Likewise, a defendant should not be able to hide every single piece of information from public view – especially where public safety may be at issue.  

Further permitting parties to litigate behind closed doors will only hurt our legal system by depriving it of insight, analysis and precedent.  When issues are so intertwined with "confidential facts" that cannot be publicly disclosed, any court order or opinion will necessarily be sealed and will therefore be hidden, likely into perpetuity.  This no doubt will lead to inconsistent rulings, interpretation of laws and results.  Such a reality is a bad result for everyone. 

Michigan Federal Court Dismisses Multiple Plaintiff Action For Failure To State A Claim

Pleading standards issues seem to be all around us these days.  Most recently, the Western District of Michigan took up the issue.  In Abnet, et al. v. Coca-Cola, Co., a case involving many plaintiffs alleging property damage due to groundwater toxicity from a nearby Coca-Cola plant, the court held that the plaintiffs failed to connect the generalized allegations in their complaint with any specific harms to many individual plaintiffs - several plaintiffs did not allege any specific individual harm.  The court further stated:

each individual Plaintiff is obligated to state how Defendants' alleged behavior gives him or her in particular a right to relief.

You can read the full OPINION here.  While specific to the plainitffs that failed to allege any specific individual harm, the Abnet opinion is worth reading as a reminder of the pleading standards under Federal Rule 8.

11th Circuit Overturns Class Certification In YoPlusYougurt Case.

In keeping with our discussion on class certifications (see below), of note is the recent decision of the 11th Circuit vacating an order certifying a class this past Friday.  In Fitzpatrick v. Gen. Mills, Inc., the class consisted of consumers who purchased YoPlus yogurt.  The products liability case alleged that General Mills violated the Florida Deceptive and Unfair Trade Practices Act (FDUTPA) by making false and misleading claims about the digestive health benefits of its YoPlus yogurt.  The District Court certified the class and held that recovery under FDUTPA does not hinge on whether a particular plaintiff actually relied on General Mills' claims about YoPlus' alleged health benefits, but rather, whether the deceptive conduct would deceive an objective reasonable consumer.

The District court concluded its order by defining the class as "all persons who purchased YoPlus in the State of Florida to obtain its claimed digestive health benefit."  Noticeably perplexed by the District court, the 11th Circuit concluded the definition of the class certified was in conflict with the District Court's sound analysis and threw into question what class it actually intended to certify.

The 11th Circuit stated simply that "the district court's analysis in its Order on Motion for Class Certification is sound and in accord with federal and state law. The reasoning reflected therein is well within the parameters of Rule 23's requirements for certification of a class. And, if the definition of the class had been in accord with the legal analysis, we would have readily affirmed." Fitzpatrick v. Gen. Mills, Inc., 10-11064, 2011 WL 1103005 (11th Cir. Mar. 25, 2011). 

While this products liability case appears to revolve around a technicality, it is important to consider the distinction here between the District court's analysis grounded in one definition of the would-be class and the conclusion that greatly limited the class by contradicting its own analysis.  It seems a foregone conclusion that the District court will simply redefine the class in accordance with its analysis and the 11th Circuit's guidance.

Supreme Court Rules 'Statistically Insignificant Information' Can Still Be 'Material Information'

On Tuesday, The Supreme Court Ruled 9-0 in favor of the investors in Matrixx Initiatives v. Siracusano (09-1156), March 22, 2011. 

We all may remember well the countless television and radio advertisements for Zicam cold remedy.  But when reports began to surface that some users of the Zicam cold remedy (now a discontinued product) had lost their sense of smell, the manufacturer, Matrixx Initiatives, Inc., saw shares of its stock lose value. In an effort to stem the tide of negative publicity, Matrixx issued statements defending its popular cold medicine by first dismissing the incidence of the loss of sense of smell as exceedingly rare and then taking the additional bold step of proclaiming that there was no scientific basis for linking Zicam to the complained of side effect.

Investors brought class action against Matrixx Initiatives and three of its executives, alleging that they violated federal securities laws by failing to disclose material information about Zicam.  The investors had learned that Matrixx had, on a handful of occasions, been contacted by the medical community regarding the link between the use of Zicam and the loss of smell.  Further, Matrixx made statements about product sales and growth without disclosing that the company had been sued upon claims of loss of smell resulting from the use of Zicam.

The Supreme Court was faced with the question of whether a plaintiff can state a claim for securities fraud under § 10(b) of the Securities Exchange Act of 1934, and Securities and Exchange Commission (SEC) Rule 10b-5, based on a Matrixx’s failure to disclose reports of adverse events associated with its product Zicam if the reports do not disclose a statistically significant number of adverse events.

The Supreme Court held that information regarding a side effect of a drug, even if the side effect is extremely rare, was ‘material information’ upon which a ‘reasonable investor’ may have acted.  The decision now clears the way for the investor class-action lawsuit to move forward against Matrixx, holding that the company had an obligation to reveal details of the observed side effects to investors even though the Company claimed the information did not rise to the level of statistically significant data.

A lack of statistically significant data does not mean that medical experts have no reliable basis for inferring a causal link between a drug and adverse events ... We note that courts frequently permit expert testimony on causation based on evidence other than statistical significance.

Given that medical professionals and regulators act on the basis of evidence of causation that is not statistically significant, it stands to reason that in certain cases reasonable investors would as well.

What is important to recognize here is that Martixx made affirmative statements denying the association between Zicam and loss of smell and omitted certain facts and information relating to those side effects.  Simply, Matrixx was not required to provide the information it had.  However, once Matrixx made satements and representations regarding Zicam, those statements needed to be complete and accurate.

...it bears emphasis that § 10(b) and Rule 10b-5(b) do not create an affirmative duty to disclose any and all material information. Disclosure is required under these provisions only when necessary “to make ... statements made, in the light of the circumstances under which they were made, not misleading.

The Court reasoned that there is no bright line rule requiring statistically significant information embracing, rather, a “total mix” standard of whether a reasonable investor would have viewed the non-disclosed information as significantly altering the total mix of information available to the investing public.

The question remains whether a reasonable investor would have viewed the nondisclosed information ‘as having significantly altered the “total mix” of information made available.’

... the mere existence of reports of adverse events-which says nothing in and of itself about whether the drug is causing the adverse events-will not satisfy this standard. Something more is needed, but that something more is not limited to statistical significance and can come from “the source, content, and context of the reports...

The Court's analysis in Matrixx is important to consider when deciding what information your company should make public.  As is so often the case, the mouth piece of the company may not be aware of certain facts or information which may cause their statements to be "misleading."  Good corporate policy regarding dissemination of information to the public and a clear understanding of that policy is critical.